Search research articles
Contact Us
Filters
Showing results (221-230 of 282) with videos related to
Page
of 29
Sort By:
The Lancet. Oncology
|
August 2, 2025
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial
Louise Emmett, Nathan Papa, Shalini Subramaniam, et al.
European Urology Oncology
|
February 11, 2020
Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Frede Donskov, Wanling Xie, Anders Overby, et al.
European Urology
|
October 29, 2015
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies
Joaquim Bellmunt, Thian Kheoh, Margaret K Yu, et al.
Nature Cancer
|
April 15, 2026
Predictive value of early PSMA upregulation for the response to enzalutamide ± <sup>177</sup>Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial
Louise Emmett, Mina Swiha, Nathan Papa, et al.
Nature Medicine
|
May 27, 2025
Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
Edmond M Kwan, Sarah W S Ng, Sofie H Tolmeijer, et al.
The Lancet. Oncology
|
December 15, 2023
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study
Enrique Grande, José Á Arranz, Maria De Santis, et al.
The Lancet. Oncology
|
December 15, 2023
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study
Aristotelis Bamias, Ian D Davis, Matthew D Galsky, et al.
Translational Andrology and Urology
|
May 10, 2021
Whole blood <i>GRHL2</i> expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer
Edmond M Kwan, Heidi Fettke, Megan Crumbaker, et al.
The Lancet. Oncology
|
October 1, 2020
Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial
Andrew Kneebone, Carol Fraser-Browne, Gillian M Duchesne, et al.
European Urology Focus
|
July 30, 2017
Development of Indicators to Assess Quality of Care for Prostate Cancer
Nupur Nag, Jeremy Millar, Ian D Davis, et al.
Page
of 29
Search research articles
Search
Showing results (221-230 of 282) with videos related to
Sort By:
Page
of 29
The Lancet. Oncology
|
August 2, 2025
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial
Louise Emmett, Nathan Papa, Shalini Subramaniam, et al.
European Urology Oncology
|
February 11, 2020
Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Frede Donskov, Wanling Xie, Anders Overby, et al.
European Urology
|
October 29, 2015
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies
Joaquim Bellmunt, Thian Kheoh, Margaret K Yu, et al.
Nature Cancer
|
April 15, 2026
Predictive value of early PSMA upregulation for the response to enzalutamide ± <sup>177</sup>Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial
Louise Emmett, Mina Swiha, Nathan Papa, et al.
Nature Medicine
|
May 27, 2025
Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
Edmond M Kwan, Sarah W S Ng, Sofie H Tolmeijer, et al.
The Lancet. Oncology
|
December 15, 2023
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study
Enrique Grande, José Á Arranz, Maria De Santis, et al.
The Lancet. Oncology
|
December 15, 2023
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study
Aristotelis Bamias, Ian D Davis, Matthew D Galsky, et al.
Translational Andrology and Urology
|
May 10, 2021
Whole blood <i>GRHL2</i> expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer
Edmond M Kwan, Heidi Fettke, Megan Crumbaker, et al.
The Lancet. Oncology
|
October 1, 2020
Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial
Andrew Kneebone, Carol Fraser-Browne, Gillian M Duchesne, et al.
European Urology Focus
|
July 30, 2017
Development of Indicators to Assess Quality of Care for Prostate Cancer
Nupur Nag, Jeremy Millar, Ian D Davis, et al.
Page
of 29